Evaluating the influence of selection markers on obtaining selected pools and stable cell lines in human cells

Biotechnology Journal

Volumn 8, Issue 7, 2013, Pages 811-821

  Lanza, Amanda M ^a   Kim, Do Soon ^a   Alper, Hal S ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Hygromycin B; Mammalian selection marker; Neomycin; Puromycin; Zeocin

Indexed keywords

FLUORESCENCE LEVEL; GREEN FLUORESCENT PROTEIN; HYGROMYCIN; MAMMALIAN CELL LINES; NEOMYCIN; PUROMYCIN; SELECTION MARKER; SELECTION PRESSURES;

ANTIBIOTICS; CLONE CELLS; CLONING; MAMMALS;

CELL CULTURE;

GREEN FLUORESCENT PROTEIN; HYGROMYCIN B; NEOMYCIN; PHLEOMYCIN; PUROMYCIN;

ARTICLE; CELL CLONE; CELL GROWTH; CELL ISOLATION; CELL LINE; CELL MATURATION; CELL POPULATION; CELL SELECTION; CELL TYPE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STABLE EXPRESSION; TRANSGENE; WILD TYPE;

HYGROMYCIN B; MAMMALIAN SELECTION MARKER; NEOMYCIN; PUROMYCIN; ZEOCIN™;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; BLEOMYCIN; CELL LINE; DRUG RESISTANCE; GENES, REPORTER; GENETIC ENGINEERING; GENETIC MARKERS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; SELECTION, GENETIC;

MAMMALIA;

EID: 84879746321     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201200364     Document Type: Article

References (43)

1. Li, F., Vijayasankaran, N., Shen, A. Y., Kiss, R., Amanullah, A., Cell culture processes for monoclonal antibody production. MAbs 2010, 2, 466-479.
2. Song, M., Raphaelli, K., Jones, M. L., Aliabadi-Zadeh, K. et al., Clonal selection of high producing, stably transfected HEK293 cell lines utilizing modified, high-throughput FACS screening. J. Chem. Technol. Biotechnol. 2011, 86, 935-941.
3. Omasa, T., Onitsuka, M., Kim, W. D., Cell engineering and cultivation of chinese hamster ovary (CHO) cells. Curr. Pharm. Biotechnol. 2010, 11, 233-240.
4. Shukla, A. A., Thommes, J., Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010, 28, 253-261.
5. Swiech, K., Picanco-Castro, V., Covas, D. T., Human cells: New platform for recombinant therapeutic protein production. Protein Expr. Purif. 2012, 84, 147-153.
6. Durocher, Y., Butler, M., Expression systems for therapeutic glycoprotein production. Curr. Opin. Biotechnol. 2009, 20, 700-707.
7. Peng, R. W., Guetg, C., Tigges, M., Fussenegger, M., The vesicle-trafficking protein munc18b increases the secretory capacity of mammalian cells. Metab. Eng. 2010, 12, 18-25.
8. Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., Oliveira, R., Guidelines to cell engineering for monoclonal antibody production. Eur. J. Pharm. Biopharm. 2009, 74, 127-138.
9. Kramer, O., Klausing, S., Noll, T., Methods in mammalian cell line engineering: From random mutagenesis to sequence-specific approaches. Appl. Microbiol. Biotechnol. 2010, 88, 425-436.
10. Seth, G., Charaniya, S., Wlaschin, K. F., Hu, W. S., In pursuit of a super producer-alternative paths to high producing recombinant mammalian cells. Curr. Opin. Biotechnol. 2007, 18, 557-564.
11. Wurm, F. M., Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22, 1393-1398.
12. Browne, S. M., Al-Rubeai, M., Selection methods for high-producing mammalian cell lines. Trends Biotechnol. 2007, 25, 425-432.
13. Wurtele, H., Little, K. C. E., Chartrand, P., Illegitimate DNA integration in mammalian cells. Gene Therapy 2003, 10, 1791-1799.
14. Wirth, M., Bode, J., Zettlmeissl, G., Hauser, H., Isolation of overproducing recombinant mammalian cell lines by a fast and simple selection procedure. Gene 1988, 73, 419-426.
15. Chusainow, J., Yang, Y. S., Yeo, J. H., Toh, P. C. et al., A study of monoclonal antibody-producing CHO cell lines: What makes a stable high producer? Biotechnol. Bioeng. 2008, 102, 1182-1196.
16. Wurm, F. M., Integration, amplification and stability of plasmid sequences in CHO cell cultures. Biologicals 1990, 18, 159-164.
17. Wurm, F. M., Petropoulos, C. J., Plasmid integration, amplification and cytogenetics in CHO cells: Questions and comments. Biologicals 1994, 22, 95-102.
18. Gurtu, V., Yan, G., Zhang, G., IRES bicistronic expression vectors for efficient creation of stable mammalian cell lines. Biochem. Biophys. Res. Commun. 1996, 229, 295-298.
19. Rees, S., Coote, J., Stables, J., Goodson, S. et al., Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 1996, 20, 102-104 106, 108-110.
20. Porter, A. J., Racher, A. J., Preziosi, R., Dickson, A. J., Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: Improving the efficiency of cell line generation. Biotechnol. Prog. 2010, 26, 1455-1464.
21. Lanza, A., Cheng, J., Alper, H., Emerging synthetic biology tools for engineering mammalian cell systems and expediting cell line development. Curr. Opin. Chem. Eng. 2012, 1, 403-410.
22. Oliva-Trastoy, M., Defais, M., Larminat, F., Resistance to the antibiotic Zeocin by stable expression of the Sh ble gene does not fully suppress Zeocin-induced DNA cleavage in human cells. Mutagenesis 2005, 20, 111-114.
23. Bernard, H. U., Krammer, G., Rowekamp, W. G., Construction of a fusion gene that confers resistance against hygromycin B to mammalian cells in culture. Exp. Cell Res. 1985, 158, 237-243.
24. Valera, A., Perales, J. C., Hatzoglou, M., Bosch, F., Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism. Hum. Gene Ther. 1994, 5, 449-456.
25. Azzam, M. E., Algranati, I. D., Mechanism of puromycin action: Fate of ribosomes after release of nascent protein chains from polysomes. Proc. Natl. Acad. Sci. USA 1973, 70, 3866-3869.
26. Pestka, S., Inhibitors of ribosome functions. Annu. Rev. Microbiol. 1971, 25, 487-562.
27. Vara, J. A., Portela, A., Ortin, J., Jimenez, A., Expression in mammalian cells of a gene from Streptomyces alboniger conferring puromycin resistance. Nucleic Acids Res. 1986, 14, 4617-4624.
28. Dekeyser, R., Claes, B., Marichal, M., Vanmontagu, M., Caplan, A., Evaluation of selectable markers for rice transformation. Plant Physiol. 1989, 90, 217-223.
29. Hauptmann, R. M., Vasil, V., Ozias-Akins, P., Tabaeizadeh, Z. et al., Evaluation of selectable markers for obtaining stable transformants in the gramineae. Plant Physiol. 1988, 86, 602-606.
30. Miki, B., McHugh, S., Selectable marker genes in transgenic plants: Applications, alternatives and biosafety. J. Biotechnol. 2004, 107, 193-232.
31. Karim, A. S., Curran, K. A., Alper, H. S., Characterization of plasmid burden and copy number in Saccharomyces cerevisiae for optimization of metabolic engineering applications. FEMS Yeast Res. 2013, 13, 107-116.
32. Cheon, S. A., Choo, J., Ubiyvovk, V. M., Park, J. N. et al., New selectable host-marker systems for multiple genetic manipulations based on TRP1, MET2 and ADE2 in the methylotrophic yeast Hansenula polymorpha. Yeast 2009, 26, 507-521.
33. Giordano-Santini, R., Dupuy, D., Selectable genetic markers for nematode transgenesis. Cell Mol. Life Sci. 2011, 68, 1917-1927.
34. Mulsant, P., Gatignol, A., Dalens, M., Tiraby, G., Phleomycin resistance as a dominant selectable marker in CHO cells. Somat. Cell Mol. Genet. 1988, 14, 243-252.
35. Kaufman, R. J., Overview of vector design for mammalian gene expression. Mol. Biotechnol. 2000, 16, 151-160.
36. Pallavicini, M. G., DeTeresa, P. S., Rosette, C., Gray, J. W., Wurm, F. M., Effects of methotrexate on transfected DNA stability in mammalian cells. Mol. Cell Biol. 1990, 10, 401-404.
37. Goldstein, A. L., McCusker, J. H., Three new dominant drug resistance cassettes for gene disruption in Saccharomyces cerevisiae. Yeast 1999, 15, 1541-1553.
38. Rasheed, S., Nelson-Rees, W. A., Toth, E. M., Arnstein, P., Gardner, M. B., Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 1974, 33, 1027-1033.
39. Graham, F. L., Smiley, J., Russell, W. C., Nairn, R., Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36, 59-74.
40. Koduri, R. K., Miller, J. T., Thammana, P., An efficient homologous recombination vector pTV(I) contains a hot spot for increased recombinant protein expression in Chinese hamster ovary cells. Gene 2001, 280, 87-95.
41. Barranco, S. C., Shilkun, K., Nichols, S., Boerwinkle, W. R. et al., Changes in DNA distributions and ploidy of CHO cells as a function of time in culture. In Vitro 1981, 17, 730-734.
42. Derouazi, M., Martinet, D., Besuchet Schmutz, N., Flaction, R. et al., Genetic characterization of CHO production host DG44 and derivative recombinant cell lines. Biochem. Biophys. Res. Commun. 2006, 340, 1069-1077.
43. Lanza, A. M., Dyess, T. J., Alper, H. S., Using the Cre/lox system for targeted integration into the human genome: loxFAS-loxP pairing and delayed introduction of cre DNA improve gene swapping efficiency. Biotechnol. J. 2012, 7, 898-908.